Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nelfinavir

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 540Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 159989-64-7, Viracept, Ag-1343, Viracept (tn), Nelfinavir (inn), Ho3ogh5d7i
    Molecular Formula
    C32H45N3O4S
    Molecular Weight
    567.8  g/mol
    InChI Key
    QAGYKUNXZHXKMR-HKWSIXNMSA-N
    FDA UNII
    HO3OGH5D7I
    A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
    Nelfinavir is a Protease Inhibitor. The mechanism of action of nelfinavir is as a HIV Protease Inhibitor, and Cytochrome P450 3A Inhibitor.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
    2.1.2 InChI
    InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1
    2.1.3 InChI Key
    QAGYKUNXZHXKMR-HKWSIXNMSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O
    2.1.5 Isomeric SMILES
    CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O
    2.2 Other Identifiers
    2.2.1 UNII
    HO3OGH5D7I
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Ag 1343

    2. Ag-1343

    3. Ag1343

    4. Mesylate, Nelfinavir

    5. Monomethane Sulfonate, Nelfinavir

    6. Nelfinavir Mesylate

    7. Nelfinavir Monomethane Sulfonate

    8. Sulfonate, Nelfinavir Monomethane

    9. Viracept

    2.3.2 Depositor-Supplied Synonyms

    1. 159989-64-7

    2. Viracept

    3. Ag-1343

    4. Viracept (tn)

    5. Nelfinavir (inn)

    6. Ho3ogh5d7i

    7. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxamide

    8. Nsc-747167

    9. Chebi:7496

    10. 1un

    11. 2-[2-hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenyl Sulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic Acid Tert-butylamide

    12. Nlf

    13. Nelfinavir [inn]

    14. Nelfinavir [inn:ban]

    15. Nfv

    16. (3s,4as,8as)-n-(tert-butyl)-2-((2r,3r)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide

    17. Chembl1205

    18. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methyl-benzoyl)amino]-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxamide

    19. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide

    20. 3-isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-((2r,3r)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3s,4as,8as)-

    21. Smr000596515

    22. Nsc722664

    23. Ncgc00090782-03

    24. Nelfinavir Mesylate Ag1343

    25. Unii-ho3ogh5d7i

    26. Met-sdf-1.beta. & Nelfinavir

    27. 1ohr

    28. 3-isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-[(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3s,4as,8as)-

    29. (3s-(2(2s*,3s*),3alpha,4abeta,8abeta))-n-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide

    30. Nelfinavir [mi]

    31. Nelfinavir [vandf]

    32. Chembl584

    33. Nelfinavir [who-dd]

    34. Bidd:pxr0143

    35. Schembl38218

    36. Mls001195634

    37. Mls001304729

    38. N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide (3s-(2(2s*,3s*),3alpha,4abeta,8abeta))-

    39. Bidd:gt0395

    40. Nelfinavir [ema Epar]

    41. Dtxsid5035080

    42. Gtpl11090

    43. Hms2232i04

    44. Met-stromal Cell-derived Factor-1.beta. (human) & Nelfinavir

    45. Zinc3833846

    46. Bdbm50061306

    47. Mfcd01938163

    48. Nsc747167

    49. Akos000280862

    50. Am84529

    51. Cs-0677

    52. Db00220

    53. Nsc 747167

    54. Mrf-0000208

    55. Ncgc00090782-04

    56. Ncgc00090782-05

    57. Ncgc00090782-17

    58. 3-isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3s-(2-(2s*,3s*),3-alpha,4a-beta,8a-beta))-

    59. Ac-20032

    60. As-75258

    61. Hy-15287

    62. 89n647

    63. C07257

    64. C73027

    65. D08259

    66. Ab00698259-15

    67. A810095

    68. A810096

    69. Q423366

    70. (3s, 4as, 8as)-2-[(2r, 3r)-2-hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic Acid T-butylamide

    71. (3s, 4as, 8as)-2-[(2r, 3r)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic Acid T-butylamide

    72. (3s,4abeta,8abeta)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-(2-methyl-3-hydroxybenzoylamino)-4-(phenylthio)butyl]decahydroisoquinoline-3alpha-carboxamide

    73. (3s,4as,8as)-2-[(2r,3r)-2-hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic Acid Tert-butylamide; Compound With Methanesulfonic Acid

    74. (3s,4as,8as)-2-[(2r,3r)-2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylthiobutyl]decahydroisoquinoline-3-carboxylic Acid T-butylamide

    75. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide

    76. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-[[(3-hydroxy-2-methylphenyl)-oxomethyl]amino]-4-(phenylthio)butyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxamide

    77. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-2-hydroxy-3-{[(3-hydroxy-2-methylphenyl)carbonyl]amino}-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide

    78. (3s,4as,8as)-n-tert-butyl-2-[(2r,3r)-3-[(2-methyl-3-oxidanyl-phenyl)carbonylamino]-2-oxidanyl-4-phenylsulfanyl-butyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxamide

    79. 3-isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2- [(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3s,4as,8as)-

    80. 3-isoquinolinecarboxamide,1-dimethyl Ethyl)decahydro-2-[(2r,3r)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, (3s,4as,8as)-

    81. 3-isoquinolinecarboxamide,1-dimethylethyl)decahydro-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylthio)butyl]-, [3s-[2(2s*,3s*),3.alpha.,4a.beta.,8a.beta.]]-

    82. N-(tert-butyl)-2-(2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl)decahydroisoquinoline-3-carboxamide

    2.4 Create Date
    2005-03-26
    3 Chemical and Physical Properties
    Molecular Weight 567.8 g/mol
    Molecular Formula C32H45N3O4S
    XLogP35.7
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count10
    Exact Mass567.31307810 g/mol
    Monoisotopic Mass567.31307810 g/mol
    Topological Polar Surface Area127 Ų
    Heavy Atom Count40
    Formal Charge0
    Complexity830
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameViracept
    PubMed HealthNelfinavir (By mouth)
    Drug ClassesAntiretroviral Agent
    Drug LabelVIRACEPT (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.VIRACEPT Tablets are available for oral administration as a light blue, capsule-shaped tablet with a clear film coating in 250 mg strength (as nelfi...
    Active IngredientNelfinavir mesylate
    Dosage FormTablet
    RouteOral
    Strengtheq 625mg base; eq 250mg base
    Market StatusPrescription
    CompanyAgouron

    2 of 2  
    Drug NameViracept
    PubMed HealthNelfinavir (By mouth)
    Drug ClassesAntiretroviral Agent
    Drug LabelVIRACEPT (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.VIRACEPT Tablets are available for oral administration as a light blue, capsule-shaped tablet with a clear film coating in 250 mg strength (as nelfi...
    Active IngredientNelfinavir mesylate
    Dosage FormTablet
    RouteOral
    Strengtheq 625mg base; eq 250mg base
    Market StatusPrescription
    CompanyAgouron

    4.2 Drug Indication

    Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.

    FDA Label

    Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.

    In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

    5.2 MeSH Pharmacological Classification

    HIV Protease Inhibitors

    Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. (See all compounds classified as HIV Protease Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    NELFINAVIR
    5.3.2 FDA UNII
    HO3OGH5D7I
    5.3.3 Pharmacological Classes
    Mechanisms of Action [MoA] - Cytochrome P450 3A Inhibitors
    5.4 ATC Code

    J05AE04

    J - Antiinfectives for systemic use

    J05 - Antivirals for systemic use

    J05A - Direct acting antivirals

    J05AE - Protease inhibitors

    J05AE04 - Nelfinavir

    5.5 Absorption, Distribution and Excretion

    Absorption

    Well absorbed following oral administration.

    Route of Elimination

    The terminal half-life in plasma was typically 3.5 to 5 hours. The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 12% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.

    Volume of Distribution

    2 to 7 L/kg

    5.6 Metabolism/Metabolites

    Primarily hepatic via cytochrome P450 (CYP450) enzymes. CYP3A and CYP2C19 appear to be the predominant enzymes that metabolize nelfinavir in humans. One major and several minor metabolites are found in plasma; the major oxidative metabolite has in vitro antiviral activity comparable to that of the parent drug.

    Nelfinavir has known human metabolites that include 3,4-Dihydroxynelfinavir and Nelfinavir hydroxyl-t- butylamide.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.7 Biological Half-Life

    3.5 - 5 hours

    5.8 Mechanism of Action

    Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.